The percentage of detection of pathogenic mutations in non-BRCA genes in patients with breast and ovarian cancers is 17.64%, which indicates that, testing of non-BRCA genes in combination of BRCA1/2 genes is equally necessary for a complete risk assessment and for developing a more accurate method for early detection, diagnosis and treatment (14, 15). Here, BRCA1 is linked to ovarian cancer.